Toursyn has recently completed consecutive Pre-A and Pre-A+ financing rounds, raising hundreds of millions of yuan in total from a consortium of well-known institutional investors. Kaicheng Capital served as the long-term exclusive financial advisor. The proceeds will be used to accelerate the advancement of the company's self-developed pipelines, upgrade its ToursynClaw one-stop AI drug design platform, and strengthen team operations and market expansion. Founded in 2023, Toursyn focuses on AI-driven protein design. Its core team brings an interdisciplinary background and has built a proprietary technology system spanning the entire protein design process, achieving a fully integrated dry-wet closed loop that can significantly shorten drug R&D cycles. The diverse mix of investors in this round combines strategic depth with industrial synergy. All parties will work together to support the company's technological iteration and pipeline implementation, and to advance the translation of AI pharmaceutical achievements.
